Serum microRNA guiding personalized radiation therapy in nonsmall cell lung cancer

Lung cancer is the most commonly diagnosed cancer and leading cause of cancer death worldwide, with an estimated 2,093,876 new lung cancers and 1,761,007 deaths from lung cancer in 2018 (1). Out of the 85% of lung cancers that are non-small cell lung cancer (NSCLC), approximately 30% of patients will present with unresectable Stage III disease for which combination chemotherapy and radiation therapy (RT) is the recommended treatment (2,3).